| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.8 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | 0.0064 | 0.8 |
| mRNA | AR-42 | GDSC1000 | pan-cancer | AAC | 0.0058 | 0.8 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.8 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |